COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation
暂无分享,去创建一个
S. Dey | M. Ghosh | Haibin Wang | E. Romeo | J. Luyendyk | N. Mackman | T. Hla | Youxi Ai | J. Peters
[1] W. S. Ho,et al. Endothelium‐dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2‐arachidonoylglycerol , 2007, British journal of pharmacology.
[2] J. Perez-polo,et al. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. , 2007, Prostaglandins & other lipid mediators.
[3] W. Wahli,et al. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression , 2006, Proceedings of the National Academy of Sciences.
[4] J. Freyssinet,et al. Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[5] S. Solomon,et al. Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas , 2006, Circulation.
[6] L. Køber,et al. Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.
[7] S. Suissa,et al. Use of First- and Second-Generation Cyclooxygenase-2–Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction , 2006, Circulation.
[8] T. Lüscher,et al. Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications , 2006, Circulation.
[9] Garret A FitzGerald,et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.
[10] Rajesh C. Dash,et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. , 2005, Cell metabolism.
[11] Lawrence J Marnett,et al. Glycerylprostaglandin Synthesis by Resident Peritoneal Macrophages in Response to a Zymosan Stimulus* , 2005, Journal of Biological Chemistry.
[12] F. Peale,et al. A monoclonal antibody that inhibits mouse tissue factor function , 2005, Journal of thrombosis and haemostasis : JTH.
[13] F. Ruschitzka,et al. Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH2 Kinase Phosphorylation , 2005, Circulation.
[14] J. Falck,et al. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. , 2005, American journal of physiology. Heart and circulatory physiology.
[15] D. Rader,et al. COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice , 2004, Science.
[16] L. Marnett,et al. Aberrant cannabinoid signaling impairs oviductal transport of embryos , 2004, Nature Medicine.
[17] R. Proia,et al. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. , 2004, Genes & development.
[18] R. Botting,et al. Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.
[19] R. Hebbel,et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. , 2004, Blood.
[20] N. Mackman. Role of tissue factor in hemostasis, thrombosis, and vascular development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[21] G. FitzGerald. Prostaglandins: Modulators of Inflammation and Cardiovascular Risk , 2004, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[22] J. Mitchell,et al. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[23] Rajnish A. Gupta,et al. Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth , 2004, Nature Medicine.
[24] C. Patrono,et al. Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[25] B. Agarwal,et al. Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells , 2003, Apoptosis.
[26] William A. Boisvert,et al. Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ , 2003, Science.
[27] L. Marnett,et al. Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol* , 2001, The Journal of Biological Chemistry.
[28] T. Willson,et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Ward,et al. Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.
[30] T. Hla,et al. Overexpression of Cyclooxygenase-2 Induces Cell Cycle Arrest , 1999, The Journal of Biological Chemistry.
[31] J. Morrow,et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.
[32] T. Hla,et al. Endothelial Cell Apoptosis Induced by the Peroxisome Proliferator-activated Receptor (PPAR) Ligand 15-Deoxy-Δ12,14-prostaglandin J2 * , 1999, The Journal of Biological Chemistry.
[33] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[34] Jasmine Chen,et al. The Peroxisome Proliferator‐activated Receptors: Ligands and Activators a , 1996, Annals of the New York Academy of Sciences.
[35] M. Gimbrone,et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[36] E. Remmers,et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. , 1994, The Journal of clinical investigation.
[37] T. Hla,et al. Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[38] T. Edgington,et al. Monoclonal antibody analysis of purified and cell-associated tissue factor. , 1988, Thrombosis research.
[39] W. Frishman. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2006 .
[40] F. Bermúdez-Silva,et al. The endocannabinoid system: physiology and pharmacology. , 2005, Alcohol and alcoholism.
[41] N. Ueda. Endocannabinoid hydrolases. , 2002, Prostaglandins & other lipid mediators.